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Abstract 
Background: Plasmodium falciparum haemozoin, a detoxification product of digested haemoglobin from infected 
erythrocytes, is released into the bloodstream upon schizont rupture and accumulates in leukocytes. High levels of 
haemozoin correlate with disease severity. Some studies have shown that concentrations of the substrate of inducible 
nitric oxide synthase (iNOS), l-arginine, as well as nitric oxide are low in patients infected with P. falciparum malaria. 
The present study investigates, in vitro, the role of P. falciparum haemozoin on nitric oxide production, iNOS expres-
sion in macrophages, and the possible interaction between l-arginine and haemozoin.
Methods: Plasmodium falciparum haemozoin was obtained from in vitro cultures through magnetic isolation. 
Phagocytosis of haemozoin by immortalized bone marrow derived macrophages was detected by confocal reflection 
combined with fluorescence microscopy. Nitrite concentrations in the supernatants was evaluated by Griess assay 
as a standard indication of nitric oxide production, while iNOS expression was detected on cell extracts by western 
blotting. Detection of l-arginine in haemozoin-treated or untreated media was achieved by liquid chromatography–
tandem mass spectrometry (LC–MS/MS).
Results: Haemozoin synergizes in vitro with interferon-gamma to produce nitric oxide. However, when mouse 
macrophages were stimulated with haemozoin, a proportional increase of nitric oxide was observed up to 25 μM of 
haemozoin, followed by a decrease with doses up to 100 μM, when nitric oxide release was completely abrogated. 
This was not due to reactive oxygen species production, nor to an effect on iNOS activity. Interestingly, when at 24 h, 
haemozoin-treated macrophages were washed and incubated in fresh medium for further 24 h, the nitric oxide pro-
duction was restored in a dose–response manner. Similar results were seen when l-arginine-enriched media was used 
in the stimulation. Moreover, muramyldipeptide, a strong nitric oxide inducer, was unable to activate macrophages to 
release nitric oxide in the presence of haemozoin-treated medium. By LC–MS/MS a complete depletion of l-arginine 
was observed in this haemozoin-treated, conditioned medium.
Conclusions: It is proposed that haemozoin interacts with l-arginine reducing its availability for iNOS, and thus 
decreasing nitric oxide production. The clinical (or pathological) implications of these results are discussed.
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Background
Malaria remains a major threatening problem worldwide 
with an annual burden of 216 million cases in 2016 and 
445,000 deaths [1], especially young children, in Africa, 
and pregnant women. The severe form of the disease is 
characterized by adherence and sequestration of infected 
erythrocytes to the vascular endothelium, associated with 
excessive inflammatory response [2]. Nitric oxide (NO), 
an innate immune mediator commonly released dur-
ing malaria infection, seems to modulate the sequestra-
tion of parasitized erythrocytes [3–5]. Indeed, protection 
from severe malaria has been shown in individuals with 
specific genetic disorders (i.e. mutations) that promote 
NO production [6]. In severe malaria cases, low levels 
of NO are present, as well as low levels of its precursor, 
l-arginine (l-Arg) [7–9], which is also associated with a 
reduced erythrocyte deformability [10]. It is also reported 
that the management of patient by treatment with l-Arg 
[7] or by inhaled NO as adjunctive therapy improves NO 
bioavailability, leading to reduction of the symptoms of 
severe malaria [11, 12]. Similar observation was made in 
murine experimental models of cerebral malaria [13–16]. 
However, contrasting data were also published. A pilot 
study presented by Yeo and colleagues showed that l-Arg 
treatment in a small cohort of malaria  patients did not 
induce changes in endothelial NO bioavailability or lac-
tate clearance, a marker of disease [17]. Also, inhaled NO 
therapy failed to improve the levels of angiopoietin-1, a 
biomarker of malaria severity [18].
Coincidentally, there is an association between severe 
malaria and Plasmodium falciparum haemozoin (HZ), a 
by-product of digested haemoglobin from P. falciparum 
infected erythrocytes, released into the bloodstream 
upon cell rupture [19–22]. Increase of l-Arg breakdown 
(free or intra-erythrocyte) has been reported elsewhere 
[23], while another report shows that l-Arg inhibits the 
formation of the synthetic pigment crystal (beta-hema-
tin, βH) [24]. There is no information so far about a pos-
sible interaction between l-Arg and HZ. The aim of the 
present study was to investigate in vitro the role of HZ in 
the modulation of NO or iNOS, and the role of l-Arg in 
this phenomenon.
Methods
Reagents
CellMask™ Plasma Membrane Stain and DAPI were 
obtained from Molecular Probes/Invitrogen (Thermo 
Fisher Scientific, Waltham, MA, USA). Protein Extrac-
tion Buffer (RIPA Buffer) and protease inhibitor cocktail 
were obtained from Axxora (USA). Polyclonal anti-iNOS 
antibody was obtained from Cell Signaling (Danvers, MA, 
USA). Mouse monoclonal anti-actin antibody, horseradish 
peroxidase (HRP)-conjugated donkey anti-rabbit, and goat 
anti-mouse antibodies were obtained from Santa Cruz 
Biotechnology Inc. (Dallas, TX, USA). Filtration supplies 
were from  Millipore® (Milan, Italy). Unless otherwise 
stated, chemical reagents were obtained from Sigma-
Aldrich (Milan, Italy), while cell culture media, serum and 
supplements, from EuroClone (Milan, Italy).
Culture of bone marrow derived macrophages
Immortalized mouse C57Bl/6 bone marrow derived 
macrophages (BMDM) from wild type lineage were 
generated and maintained in the growth medium, as 
previously reported [25, 26]. The basic composition of 
the growth medium used for BMDM consisted in Dul-
becco’s minimal essential medium, DMEM, which con-
tains 0.084 g/l of l-Arg, supplemented with l-glutamine 
(2  mM), HEPES (20  mM, pH 7.3), and 10% heat-inacti-
vated fetal bovine serum (FBS) (South America origin EU 
Approved).
Culture of P. falciparum and preparation of haemozoin
Mycoplasma-free P. falciparum parasites (strain 3D7) 
were maintained in vitro as previously described [27, 28]. 
For malaria cultures, fresh erythrocytes where obtained 
from AVIS Comunale Milano with the consent of healthy 
donors. The parasites were kept in culture at 5% haem-
atocrit (human type 0 + erythrocytes) at 37  °C in RPMI 
1640 medium supplemented with 10% heat-inactivated 
0 + human plasma, 20 mM HEPES, pH 7.4, in a standard 
gas mixture consisting of 1%  O2, 5%  CO2, 94%  N2.
The methodology to isolate HZ has been standard-
ized, applied and characterized in our previous report 
[28], with some modifications. Briefly, HZ was isolated 
using a LS column (MACS,  Miltenyi®) from P. falcipa-
rum cultures the day after parasitaemia reached > 5% 
trophozoites. Cultures at low hematocrit (~ 0.5%) were 
placed onto the column, and the free-HZ was isolated. By 
using the MACS-LS and low haematocrit, only free HZ 
was collected and not the parasitized erythrocytes. HZ 
was pelleted, resuspended in PBS, finely dispersed with 
a 1-ml syringe, and stored at 4 °C. To remove free haem 
and contaminating erythrocytes, HZ was extensively 
washed with PBS and hypotonic solution. The absence of 
free haem was confirmed by reading the OD at 405 nm 
(Soret band) in the supernatants obtained after HZ wash-
ing. Also, all HZ preparations were endotoxin-free as 
checked by the Limulus amoebocyte lysate-based assay, 
as previously described [28].
Stocks of HZ were made by pooling different prepa-
rations. Being HZ a crystal of haem molecules bound 
together, its molar concentration was calculated as haem 
equivalent, referring to the molecular weight of haem, as 
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previously reported [28]. Briefly, aliquots from HZ pools 
were diluted in 1 M NaOH, in order to obtain the heme 
monomers in solution. A standard curve of hemin was 
also prepared in NaOH 1 M. The samples were read spec-
trophotometrically at OD 405  nm (Synergy 4,  Biotek® 
microplate reader) and the concentration of haem mono-
mers in the HZ samples was extrapolated from the stand-
ard curve. The doses of HZ used for in vitro stimulations 
were chosen as relevant to biological conditions, and cal-
culated considering a parasitaemia of 1–4% and the iron 
content of trophozoites, as reported earlier [28–30].
Confocal microscopy
BMDMs were incubated with HZ (100 µM) in a 35-mm 
glass bottom tissue culture dish (MatTek) for 24  h. Cell 
membranes and DNA were stained with CellMask 
(red) and DAPI (blue), respectively. Confocal reflection 
microscopy (to visualize HZ phagocytosed by BMDM) 
combined with fluorescence microscopy was used as 
described in detail in [26], on a Leica TCS SP2 AOBS 
confocal laser-scanning microscope.
Stimulation of bone marrow derived macrophages 
for nitric oxide induction
BMDM were seeded and incubated overnight (96-well 
plates, 1 × 105 cells/well). Next day, the cells were primed 
with 12.5  U/ml Type I Interferon-gamma (IFN-γ) for 
2 h, or left untreated, and then stimulated with different 
concentrations of HZ (12.5, 25, 50, 100 µM). Muramyldi-
peptide (MDP) (2  µg/ml) or lipopolysaccharide (LPS) 
(200 ng/ml) were used as positive controls. After 24 h of 
incubation, the supernatants were collected and used for 
NO determination by the Griess reagent. These superna-
tants are referred as “24 h”. Fresh medium was then added 
and an extra incubation time of 24 h was carried out. The 
“24 h + 24 h” supernatants were collected and assayed for 
NO content. In some experiments, fresh medium was 
added again, further 24 h incubation was performed and 
the “24  h + 24  h + 24  h” supernatants collected for NO 
measurement by Griess reagent.
Experiments with l‑arginine‑enriched media
BMDM were seeded as explained above. Medium was 
replaced with fresh standard medium or with medium in 
which l-Arg was added to obtain ten-fold concentration 
of l-Arg (840  mg/l) (l-Arg 10×) with respect to the l-
Arg content (84 mg/l) of the standard media formulation 
(DMEM). Respective media (standard medium or l-Arg 
10×) were used for all the experimental steps described 
below. Cells were primed for 2 h with 12.5 U/ml IFN-γ, 
and then treated with medium, HZ (25 or 100 µM), MDP 
(2 µg/ml), or LPS (200 ng/ml) for 24 h or 24 h + 24 h. At 
each time point, the production of NO was determined 
by the Griess reagent.
Griess assay for nitric oxide determination
To measure NO production, the indirect measure of 
the accumulation of nitrite in the cell supernatants was 
evaluated by the Griess reagent, a standard assay largely 
used in different models [28, 31–33]. The Griess reagent 
consists of a mixture of equal parts of Reagent A (1% 
[w/v] sulphanilamide), and Reagent B (0.1% [w/v] naph-
thylethylenediamine dihydrochloride, and 2.5% [w/v] 
phosphoric acid). One hundred microliters of superna-
tants were mixed with an equal volume of Griess mix-
ture and after 10 min of incubation at room temperature, 
the nitrite levels were measured by a spectrophotometer 
(Synergy 4 microplate reader,  Biotek®, GE) at 540  nm. 
To determine the levels of nitrite, a standard curve of 
 NaNO2 was prepared in parallel to the samples.
Experiments with haemozoin‑conditioned medium
Medium alone or in the presence of HZ (200  µM) was 
incubated overnight at 37 °C under an atmosphere of 5% 
 CO2. HZ-treated medium was centrifuged (3000  rpm, 
10 min), and supernatants were filtered (0.20 µm/PSFV). 
The presence of free haem was excluded spectrophoto-
metrically, as described above. The HZ-treated medium 
will be referred as HZ-conditioned medium (HZ-CM). 
The medium alone (untreated conditioned medium, 
U-CM) received the same handling as the HZ-CM.
BMDM were seeded and incubated overnight, as 
described above. The medium was then replaced with 
U-CM or HZ-CM. Then, both priming with IFN-γ and 
the treatments with HZ (25 or 100  µM), or MDP (1 or 
2 µg/ml) were performed in U-CM or HZ-CM. The plates 
were incubated for 24  h and the levels of nitrite were 
determined in the supernatants by the Griess reagent.
Determination of reactive oxygen species release 
by stimulated bone marrow derived macrophages
BMDM were seeded in 96-well plates (1 × 105 cells/well), 
at 37  °C under an atmosphere of 5%  CO2. After 24  h, 
cells were primed or not with IFN-γ 12.5  U/ml for 2  h, 
and then stimulated with medium, HZ (25 or 100  μM), 
MDP (2 μg/ml), or tert-butyl hydrogen peroxide (t-BHP, 
10 µM). After 0.5, 18 or 48 h, cells were washed with PBS, 
and then the levels of reactive oxygen species (ROS) were 
measured by treating stimulated BMDM for 15 min with 
50  µl of 2′7′-dichlorofluorescein diacetate  (H2DCFDA, 
15 µM). Then, the cells were washed with PBS, and 200 µl 
PBS were added to each well for 30 min; 150 µl of super-
natants were transferred into a flat-bottom black plate, 
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and ROS were measured, and recorded as fluorescence 
units (FU) (Ex/Em:485 nm/535 nm; Synergy 4,  Biotek®).
Western blotting
BMDM were plated in 6-well plates (3 × 106 cells/well), at 
37 °C under an atmosphere of 5%  CO2. At the end of an 
overnight incubation, the cells were primed or not with 
IFN-λ for 2 h and then treated with medium, HZ (25 or 
100  μM), or MDP (5  μg/ml). The plates were incubated 
for 6 h, 24 h, or 24 h + 24 h. After each time point, cells 
were washed several times in ice-cold PBS, lysed in RIPA 
buffer (50  mM TRIS–HCl [pH 7.5], 105  mM NaCl, 1% 
NP-40, 1% sodium deoxycholate, 0.1% sodium dode-
cyl sulfate [SDS] and 2 mM ethylenediamine tetraacetic 
acid [EDTA]) and protease inhibitor cocktail, and incu-
bated on ice for 15  min. The lysate was centrifuged at 
15,000  rpm for 15  min at 4  °C. Equal amounts of pro-
teins of each sample supernatant (50  µg), determined 
by Bradford method [34], were separated by electro-
phoresis on 7.5% SDS–polyacrylamide gel (SDS-PAGE). 
Electrophoresed proteins were transferred onto PVDF 
membranes (Bio-Rad, Richmond, CA, USA) with the 
Bio-Rad Transfer Blot Apparatus at 150  mA for 16  h 
at 4  °C using 25  mM Tris HCl, 190  mM glycine, 20% 
methanol, and 0.05% SDS as transfer buffer. The mem-
branes were then blocked for 2 h and 30 min in blocking 
buffer (TTBS: 0.5% Tween-Tris-buffered-saline) with 5% 
bovine serum albumin (SIGMA, St. Louis, MO, USA)]. 
The blots were incubated with the specific primary anti-
body (mouse polyclonal anti-iNOS antibody), and mouse 
monoclonal anti-Actin antibody for 16 h at 4 °C in block-
ing buffer, washed 6 times for 5 min each in TTBS and 
incubated with the proper secondary horseradish per-
oxidase (HRP)-linked IgG antibodies (donkey anti-rabbit 
and goat anti-mouse), at room temperature in blocking 
buffer. After 1 h incubation, the membranes were washed 
and incubated again in TTBS, and finally developed with 
the ECL western blotting detection reagents (GE Health-
care Life Sciences, UK) following the instructions of the 
manufacturer. Immunoreactive proteins were visualized 
by autoradiography on Amersham Hyperfilm™ ECL™ 
(GE Healthcare Life Sciences, UK).
Quantitative analyses of immune reactive proteins were 
performed by digital scanning (CAMAG VideoStore 
3.00.0.06 serial n° 0607C003 and VideoScan TLC/HPTLC 
Evaluation Software version 1.01.00 serial n° 0607D003).
Experiments with liquid chromatography–tandem mass 
spectrometry
A quantitative analysis of l-Arg in the medium was 
done through the liquid chromatography–tandem 
mass spectrometry (LC–MS/MS) technique described 
elsewhere [35]. Briefly, standard medium (MED) or 
medium seven times more concentrated in l-Arg than 
standard medium (MED l-Arg 7×) were prepared as 
controls. A final concentration of 200  μM of HZ was 
prepared as HZ-CM in standard culture medium or in 
MED l-Arg 7× (HZ-CM l-Arg 7×). l-Arg (40  ng/ml) 
was used as control.
The time retention values, converged in the peak 
areas (area), were evaluated for each sample. Area 
values were determined for an internal control of 
l-Arg (40  ng/ml), medium (untreated conditioned 
medium, U-CM), medium treated with HZ 100  μM 
(haemozoin-conditioned medium, HZ-CM), medium 
enriched with l-Arg (U-CM l-Arg 7×), or HZ-CM 
enriched with l-Arg (HZ-CM l-Arg 7×). Before the 
chromatographic analyses, samples were prepared 
and incubated at 37  °C for 24  h under an atmos-
phere of 5%  CO2. Next, media were centrifuged and 
filtered (0.20  µm/PSFV). The area corresponding to 
the content of l-Arg exhibited by each treatment was 
retrieved. The mobile phases used are displayed in 
Table 1.
The instrument conditions were as follows: capil-
lary temperature 275 °C; spray voltage 5.00 kV, sheath 
gas flow rate 60 (arb); auxiliary gas flow rate 15 (arb). 
Numbers in columns (“Phase A” and “Phase B”) repre-
sent the percentage (%) of the respective eluent.
The quantifier and qualifier transition for l-Arg was 
175 > 158. Electrospray ionization in positive mode 
(ESI +) experiments was performed using a tridimen-
sional ion trap-mass spectrometer (DECA XP MAX, 
Thermo Fisher). The data were acquired by means of 
XCalibur (Thermo Fisher) software.
Statistical analyses
Differences between groups were analyzed by one-way 
or two-way ANOVA analysis and post-hoc multiple 
comparisons tests (Bonferroni, Sidak, Tukey), using the 
software GraphPad Prism 6. Data are representative of 
at least three independent experiments in triplicate.
Table 1 LC–MS/MS phases
The mobile phases of the LC–MS/MS were water plus formic acid 0.1% (Phase A), 
and  CH3CN plus formic acid 0.1% (Phase B). Gradients, at a flux 0.3 ml/min, were 
passed through the chromatographic column (Waters Atlantis C185 µm)
Time (min) Phase A Phase B
0 100 0
5 100 0
8 0 100
20 0 100
21 100 0
28 100 0
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Results
Nitric oxide production by interferon gamma primed 
macrophages stimulated with haemozoin follows 
a bell‑shaped, dose–response curve
BMDM were treated for 24 h with HZ, which was read-
ily phagocytosed, as evaluated by confocal microscopy 
(Fig.  1). Priming of BMDM with IFN-γ, shown to be 
required for the production of nitric oxide (NO) upon HZ 
stimulation, was always performed before treatment with 
different concentrations of HZ [28]. Detectable levels of 
NO were observed at 24 or 48 h but not at 6 h of incuba-
tion, therefore the majority of the experiments were done 
at 24 h. The nitrite levels released into the supernatants 
were evaluated as a measure of NO production. Figure 2a 
shows that doses of HZ up to 25  µM linearly increased 
NO production, but, unexpectedly, higher doses, from 50 
to 100 µM, induced an inverse dose–response. 
To exclude that the decrease in nitrite levels was 
due to a possible oxidation of nitrite to nitrate by HZ, 
in some experiments, all nitrate were converted into 
nitrite and the total nitrite levels in the supernatants 
were measured using the Griess reagent. The results 
were comparable to those obtained measuring only 
nitrite (Additional files 1, 4), indicating that the lower 
amount of nitrite observed with high doses of HZ was 
not due to the oxidation of nitrite to nitrate.
It has been shown that ROS can modulate NO pro-
duction [36], and that both HZ [37] and βH, the syn-
thetic HZ, induce ROS [38]. Thus, to investigate 
whether oxidative stress could be involved in the lower 
levels of NO found in the supernatants of BMDM 
treated with increasing concentrations of HZ, ROS 
release by primed or unprimed BMDM was tested. The 
lowest (25  µM) and the highest dose (100  µM) of HZ 
Fig. 1 Phagocytosis of HZ by bone marrow derived macrophages. 
BMDMs were incubated with HZ (100 µM) for 24 h. Cell membranes 
and DNA were stained with cell mask (red) and DAPI (blue), 
respectively. Confocal reflection microscopy was used to visualize 
HZ (green). Scale bar: 20 μm. The Leica TCS SP2 AOBS confocal 
laser-scanning microscope was set to allow 10% of laser light into the 
collection channel. Fields are representative of at least ten fields of 
view and three independent experiments
Fig. 2 Levels of NO and ROS induced by HZ in BMDM. BMDM 
were primed with IFN-γ for 2 h, and then treated with medium or 
different concentrations of HZ (12.5, 25, 50, 100 µM). Levels of 
nitrite (vertical axis) released into the supernatants after 24 h were 
measured. *P < 0.01, *** #P < 0.0001 vs control medium. Data displayed 
as averages ± SD of three independent experiments (a). BMDM 
were primed or not for 2 h. Cells were then stimulated with HZ 
(25 or 100 µM), MDP (2 µg/ml), or tert-butyl hydroperoxide (t-BHP) 
(10 µM). After each time point (0.5, 24 or 48 h) the supernatants were 
discarded and the cells were treated with 2′,7′-dichlorofluorescein 
diacetate (DCFDA) (15 µM) for 30 min at 37 °C. The cellular oxidative 
stress induced in macrophages was measured using the Synergy4 
(BioTek) fluorescent microreader and the fluorescent units (FU, vertical 
axis) were recorded and correlated to the levels of ROS produced. 
#P < 0.0001 vs control medium. Data represent averages ± SD of three 
independent experiments (b)
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were chosen from the previous experiments. In addi-
tion, cells treated with medium only or activated by 
control agents such as MDP, a bacterial cell walls com-
ponent [39], or tert-butyl hydrogen peroxide (t-BHP) 
were included. Tert-butyl hydrogen peroxide was used 
as a positive control since it is an organic peroxide, able 
to induce ROS formation to levels similar to hydrogen 
peroxide, but with less cellular toxicity [40]. As shown 
in Fig. 2b, at 0.5 h HZ induced low but significant lev-
els of ROS only at 100 µM, but not at 25 µM. At 18 h, 
HZ induced a dose-dependent increase of ROS. This 
activity was independent of priming, as there were no 
differences in unprimed or primed cells. In addition, 
MDP or t-BHP stimulated the production of ROS in the 
same manner at 18  h (Fig.  2b). After 48  h incubation, 
the levels of ROS induced by all stimuli did not change 
significantly compared to 18  h, indicating that ROS 
produced from activated BMDM reached a plateau 
concentration already at 18  h. Collectively, these data 
indicated that, at all time points, HZ induced ROS in 
a dose-dependent manner. This result does not reflect 
the inverse dose–response of NO production induced 
by HZ, reported in Fig. 2a.
It has been described that free haem can compro-
mise the transport of l-Arg in the erythrocytes [23]. To 
exclude a possible involvement of free haem in the reg-
ulation of NO production, HZ was extensively washed 
and the presence of free haem, as well as of haemoglo-
bin, was measured and excluded in any preparations 
used.
Since l-Arg is a substrate also for Arginase-1, the 
activation of this enzyme by HZ was also excluded. 
The levels of urea, the main product of arginase activ-
ity, in cellular extracts from macrophages treated with 
HZ were comparable to those observed in untreated 
cells (Additional files 2, 4). In addition, in murine 
macrophages, arginase-1 is known to be regulated by 
Th2 cytokines, such as IL-4, IL-10, and IL-13 [41–43], 
whereas IFN-γ is needed for iNOS up-regulation. In 
our mouse macrophages model IFN-γ was used for 
iNOS induction and thus for NO release from treated 
macrophages.
Expression of inducible nitric oxide synthase does 
not match nitric oxide production by macrophages treated 
with different concentrations of haemozoin
To investigate whether HZ, according to the concentra-
tion used, induces iNOS expression in BMDM, the levels 
of iNOS were assessed at different time points by west-
ern blotting. As expected, unprimed macrophages did 
not express iNOS at any time point tested, while primed 
cells expressed low levels of iNOS even in the absence of a 
stimulus (Fig. 3). Primed macrophages treated for 6 h with 
HZ at 25 or 100 µM expressed high iNOS levels, compa-
rable to those induced by MDP. The levels of iNOS peaked 
at 6 h, with a progressive decrease at the additional time 
points. At 24  h and at 24  h + 24  h, after washing and 
medium replacement, HZ induced iNOS in BMDM only 
at the dose of 100 μM. Levels of iNOS expression in cells 
treated with MDP were higher than medium at both 
6 and 24  h, but disappeared at 24  h + 24  h. Overall, the 
iNOS expression in BMDM stimulated with HZ followed 
a kinetic similar to that induced by MDP (i.e. decrease 
in iNOS expression over time) and was dose-dependent. 
This is at variance with what observed for the NO levels 
and indicates that the production of NO by BMDM stim-
ulated with HZ does not reflect the levels of iNOS.
Fresh medium replacement restores nitric oxide 
production by macrophages treated with haemozoin 
in a dose–response manner
To investigate the inverse relationship between the doses 
of HZ and NO production, primed BMDM were treated 
Fig. 3 Levels of iNOS protein and of NO detected in HZ-treated 
BMDM. BMDM were primed or not for 2 h. Cells were treated with 
medium, HZ (25 or 100 µM), or MDP (2.5 µg/ml). Cell lysates were 
collected after 6, 24, or 24 h + 24 h. Equal amounts of proteins for 
each sample were electrophoresed, and transferred onto PVDF 
membranes. iNOS and actin proteins were probed with their 
respective antibodies. Vertical axis shows the ratios of iNOS/actin 
values. Results shown are representative of three independent 
experiments
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with medium, different concentrations of HZ, or MDP 
for 24 h. At the end of the incubation, the supernatants 
were collected and used for NO determination. Fresh 
medium was then added to both stimulated and unstim-
ulated cells. One or two extra incubation times of 24 h 
each where then carried out, the supernatants recovered 
and assayed for NO content. As depicted in Fig.  4, the 
levels of NO released during the first 24 h were inversely 
related to the HZ dose, whereas NO induced by MDP 
was significantly higher than medium. Surprisingly, 
and opposite to what observed after the first 24  h, the 
levels of NO detected in the 24  h + 24  h supernatants 
increased considerably compared to the first 24  h and 
were proportional to the dose of HZ used. Moreover, 
in the supernatants recovered at the end of the follow-
ing 24 h of incubation (i.e. 24 h + 24 h + 24 h), the lev-
els of NO were lower than at 24 h + 24 h, but retained a 
direct proportionality with the dose of HZ. The release 
of NO by cells treated with MDP at both time points was 
comparable to that at 24  h. It seems thus that medium 
replacement after the first 24  h of stimulation of HZ 
restores the dose–response for NO production, which 
seems to peak after 24 h + 24 h and decreases in the fol-
lowing 24 h.
Excess of l‑arginine in the media restores nitric oxide 
production by haemozoin
The observation that media replacement after 24  h 
restored the dose-dependent production of NO by 
HZ-treated BMDM and that iNOS was not a limiting 
factor led to the hypothesis that the availability of l-
Arg, the substrate of iNOS, could be low or reduced 
in the groups where HZ was also present. To verify 
this hypothesis, the experiments were repeated by 
stimulating BMDM using an l-Arg-enriched medium 
in which l-Arg was added to reach final concentration 
ten-fold higher than that of the standard medium (l-
Arg 10×). The levels of NO were evaluated both after 
24 h and after medium change at 24 h + 24 h (Fig. 5a). 
In all cases, the stimulation of primed BMDM with 
medium, HZ (25 or 100  µM), MDP, or LPS led to an 
increase of NO production. Using medium with l-Arg 
10×, a further increase of NO production was seen 
in all groups, and, in particular, in the sample treated 
with 100 µM of HZ, which did not induce NO in the 
standard medium. The dose of HZ was positively cor-
related with the production of NO, and opposite to 
what observed in normal medium conditions. There-
fore, it appears that an excess of l-Arg in the medium 
restores the production of NO induced by high HZ 
doses (100  µM), indicating a possible interaction 
between l-Arg and HZ.
Haemozoin decreases nitric oxide production by limiting 
l‑arginine availability
To investigate the ability of HZ to directly reduce l-Arg 
availability, a HZ treated-conditioned medium (HZ-
CM) was prepared, as described in the “Methods” sec-
tion. Untreated conditioned medium (U-CM) was also 
prepared. BMDM were treated with different concen-
trations of HZ or MDP either in U-CM or HZ-CM. The 
production of NO by both doses of HZ or MDP was 
abolished when the stimuli were prepared in HZ-CM, 
but not in U-CM (Fig.  5b). Being l-Arg the substrate 
of iNOS, these results suggested that HZ might interact 
with l-Arg, present in the culture medium, depleting 
the medium of the substrate for iNOS, thus reducing 
NO production.
To measure the effective presence of l-Arg, U-CM and 
HZ-CM were analysed by LC–MS/MS. A control of l-
Arg (40 ng/ml) was run on the column (Table 2), exhibit-
ing a peak area of 384,603. The peak area of U-CM, which 
contains 40 ng/ml of l-Arg, was 501,886. In contrast, in 
the HZ-CM no l-Arg was detected (Table  2). To better 
quantify the amount of l-Arg that interacted with HZ, 
Fig. 4 NO production by BMDM stimulated with HZ after medium 
replacement. BMDM were primed for 2 h, and treated with HZ (25, 50, 
or 100 µM), or MDP (2 µg/ml). After 24 h incubation, the supernatants 
were removed and the levels of nitrite were determined. Fresh 
medium was added to the cells and further 24 h incubation was 
performed (24 h + 24 h). Supernatants were collected again, and 
the nitrite levels determined. Incubation with fresh medium was 
carried out for further 24 h (24 h + 24 h + 24 h). The supernatants 
were collected at the end of incubation, and the nitrite levels were 
determined. #P < 0.01 and *P < 0.05 vs control medium at each 
time point; **P < 0.01 24 h + 24 h vs 24 h; £P < 0.01 24 h + 24 h vs 
24 h + 24 h + 24 h. NS not significant. Data represent averages ± SD 
of three independent experiments
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a preparation of HZ-CM and U-CM was made using a 
medium containing l-Arg 7 times more concentrated 
than in normal medium (HZ-CM l-Arg 7× and U-CM 
l-Arg 7×, respectively). The samples were then run in a 
LC–MS/MS column and it was found that the peak area 
exhibited by U-CM l-Arg 7× was 1.7 times higher than 
HZ-CM l-Arg 7×.
Discussion
The present study provides the first in vitro evidence of 
the interaction between HZ and l-Arg, leading to lower 
availability of l-Arg, the substrate for iNOS, and thus 
reduced production of NO by activated macrophages.
This finding came from an unexpected observation that 
the levels of NO released by activated BMDM followed a 
bell-shaped curve, as the HZ concentration increased. At 
doses of HZ above 25 µM the production of NO progres-
sively declined. This phenomenon was not related to ROS 
production, or to decreased iNOS expression in mac-
rophages. The NO scavenger effect of haem or haemo-
globin was excluded since all the HZ preparations were 
extensively washed and resulted free of haem or haemo-
globin contamination. The linear dose–response of NO 
production by HZ was restored by changing medium or 
adding 10× excess of l-Arg in the culture, suggesting a 
depletion of l-Arg from the culture medium more than 
a problem of macrophage activation. Subsequent experi-
ments by LS–MS–MS indeed demonstrated that purified 
HZ deprives the medium of l-Arg, probably through a 
molecular interaction between HZ and l-Arg.
HZ is an insoluble crystal consisting of Fe(III)PPIX 
(haem) bound to proteins, lipids or DNA of parasite or 
host origin [44–46]. Once released at schizont rupture, it 
is rapidly taken up by phagocytic cells (see Fig. 1), with-
out being degraded [47]. It has been demonstrated that 
Fig. 5 NO production by BMDM treated with HZ and cultured 
in medium enriched in l-Arg (a) or in HZ-conditioned medium 
(b). BMDM were plated overnight in either standard medium or 
medium enriched with l-Arg (l-Arg 10×). Respective media (standard 
medium or l-Arg 10×) were used for all the experimental steps 
described below. Cells were primed for 2 h, and then stimulated 
with medium, HZ (25 or 100 µM), MDP (2 µg/ml), or LPS (200 ng/ml) 
for 24 h. Levels of nitrite were determined, and fresh medium was 
replaced. After additional 24 h incubation (24 h + 24 h), the nitrite 
levels in the supernatants were determined again. *P < 0.05 and 
**P < 0.01 vs standard medium at each time point. Data displayed as 
averages ± SD of three independent experiments (a). BMDM were 
plated overnight in either standard medium (unconditioned medium, 
U-CM) or in HZ-conditioned medium (HZ-CM). Respective media 
(U-CM or HZ-CM) were used for all the experimental steps described 
below. Cells were primed for 2 h, and then stimulated with medium, 
HZ (25 or 100 µM), or MDP (1 or 2 µg/ml) for 24 h. Levels of nitrite 
were measured in supernatants. #P < 0.01 vs control medium, §P < 0.01 
vs U-CM. Data displayed as averages ± SD of three independent 
experiments (b)
Table 2 Determination of  l-Arg in  different samples 
of medium through LC–MS/MS
a Samples injected to the columns of the LC–MS/MS
b Area (expressed as arbitrary unit) calculated from the LC–MS/MS
c l-Arg at a concentration of 40 ng/ml
Samplea Areab
l-Argc 384,603
U-CM 501,886
HZ-CM 0
U-CM l-Arg 7× 3,418,162
HZ-CM l-Arg 7× 1,988,197
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HZ can affect the function of macrophages through dif-
ferent pathways such as TLR9 or NOD2 pathway [28, 44, 
48], or NLRP3 [25, 49]. Both stimulatory and inhibitory 
immune properties of HZ in  vitro have been described 
and depend on the source of macrophages, the protocols 
and the co-stimuli used for the functionality assays, and 
the methods of isolation and purification of HZ from par-
asite cultures [25, 32, 38, 44]. In the present study, to bet-
ter mimic the in vivo situation, only the pigment released 
free at schizont rupture into the P. falciparum culture 
medium was selected, purified and used in the assays. 
Nonetheless, additional variables, namely the constitu-
ents of the culture media or supplements (like serum), 
may account for the differences observed in functionality 
experiments.
Among its immunomodulating activities, HZ can 
induce the production of NO by mouse or human mac-
rophages from different sources [28, 38, 50]. In mac-
rophages, both eNOS and iNOS isoforms are present 
and can produce NO after homodimerization with other 
molecules such as haem, calmodulin, tetrahydrobiop-
terin, flavins [51]. The levels of iNOS in macrophages 
are significantly higher than those of eNOS [52], and 
therefore more relevant in the present model. Here, it is 
shown that iNOS expression was not congruent with NO 
levels released from macrophages stimulated with differ-
ent concentrations of HZ. This observation is in accord-
ance with clinical data from a study performed in Papuan 
(Indonesia) patients showing no correlation between 
iNOS activity in peripheral blood mononuclear cells and 
plasma concentrations of nitrite and nitrate [53].
Phagocytosed HZ can destabilize the phagosome integ-
rity, as hypothesized by Kalantari and colleagues [25]. 
Thus, the presence of HZ in the cytosol may deprive the 
cells from intracellular l-Arg. Chemically, the interaction 
between HZ and l-Arg is not unlikely. The HZ crystal 
is highly ordered with a known structure [29]. The end 
faces of the needle-like crystals expose haem propionate 
groups. The hydrogen bonding interaction between the 
carboxylate group of a propionate and the guanidinium 
side chain of arginine is very strong because of the pres-
ence of two parallel H-bonds with the added electrostatic 
interaction arising from the positive charge of the guand-
inium group attracting the negative charge of the carbox-
ylate group. Thus, an interaction between HZ and l-Arg 
can be expected. Indeed, Uyen and colleagues showed 
that basic amino acids, such as l-Arg or l-Lysine (l-Lys), 
inhibit the formation of βH [24], the synthetic crystal 
made only of the haem portion of HZ, indirectly demon-
strating the interaction of l-Arg with haem. However, in 
the present experiments, synthetic βH, differently from 
native HZ, was not able to reduce NO production even 
at the dose of 60 µM (Additional files 3, 4) suggesting that 
the l-Arg–HZ interaction requires also a component of 
HZ, not yet identified. In any case, it is difficult to imag-
ine that this depletion can arise from anything else than 
binding of l-Arg to HZ (or molecules associated with 
HZ), since no other component differs between the con-
trol and HZ containing media. Direct methods to visual-
ize l-Arg binding to HZ are not available since HZ is a 
macroscopic crystal approximately 0.5 µM in length and 
l-Arg is a small molecule. Adsorption of l-Arg from the 
medium is the only practical way to demonstrate such 
interaction. The fact that the addition of excess l-Arg to 
the culture medium results in incomplete depletion, sug-
gests a saturated binding.
The observation that HZ removes l-Arg from the 
culture medium might have clinical implications, as 
high release of HZ, low levels of l-Arg and/or NO are 
reported to be associated with severe malaria [7, 8, 11, 
19–22, 54–56].
How the bioavailability of NO contributes to the 
status of severe malaria is still controversial [11, 13]. 
Disease severity in Tanzanian children has been asso-
ciated with low levels of NO [54]. This might result in 
microvascular obstruction, tissue ischemia, and clini-
cal complications. Further evidence is provided by ani-
mal models: protection against experimental cerebral 
malaria has been reported by treatments with inhaled 
NO or NO donors [14, 15].
Host components have been linked to low levels 
of NO during malaria: free haemoglobin, from burst 
of infected erythrocytes or intravascular hemolysis, 
which scavenges NO [57]; the activation of arginase, 
in infected or uninfected erythrocytes, which catalyzes 
the production of ornithine and urea from l-Arg [58]; 
the presence of endogenous iNOS inhibitors such as 
methylated arginines (asymmetric dimethylarginine 
[ADMA] and symmetric dimethylarginine [SDMA] 
[59]); the decreased levels of tetrahydrobiopterin, 
which uncouples iNOS [60]. Yet, the availability of l-
Arg, the iNOS substrate, would definitely represent the 
limiting factor for NO production.
Hypoargininaemia is a common feature exhibited in 
both children and adults with severe malaria [19, 20, 61]. 
One of the proposed causes, although controversial, of 
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l-Arg depletion is the increase of arginase activity gener-
ated by parasites or host cells [58, 62, 63], but no report 
in the literature seems to link malaria haemozoin and 
arginase-1 activation, so far. In addition, the results here 
showed that HZ does not seem to activate this enzyme. 
Hypoargininaemia may also derive from an excess of free 
haem which dysregulates the metabolism and the avail-
ability of l-Arg. An earlier report from our group shows 
that free haem increases intra- and extra-erythrocyte l-
Arg [23]. The hypothesis proposed in this study is that 
HZ release into the circulation can contribute to hypoar-
gininaemia. This is plausible, since low levels of l-Arg 
have been associated to high parasitaemia and severe 
malaria, and both conditions are associated to high levels 
of HZ. It is conceded here that HZ may not constitute the 
exclusive cause of hypoargininaemia or of decreased lev-
els of NO in malaria, as a number of other factors could 
contribute to this activity, too. Hitherto, the data pre-
sented here might bring new insights into the pathogen-
esis of the disease concerning the relationships between 
severe cases of malaria and HZ accumulation in leuko-
cytes or bone marrow [64]. T-lymphocyte functions are 
also regulated by l-Arg bioavailability [65] thus hypoar-
gininaemia might also affect adaptive immunity during 
malaria.
The use of l-Arg for adjunctive therapy during cerebral 
malaria has been questioned; however, several reports 
show its relevance as a complement for antimalarial 
therapy during the early course of the infection [11], as 
enhancer of NO production, well known for its antiad-
hesive properties [5]. Hypoargininaemia during malaria 
infections has been also correlated with reduced P. fal-
ciparum erythrocytes deformability [10]. This may be 
relevant for the gametocytes, the transmission stage of 
malaria parasites, which sequester and develop in the 
bone marrow, from where they egress [66, 67] as a conse-
quence of increased deformability [68, 69]. HZ accumu-
lates in the bone marrow [22, 70] where it may interact 
with l-Arg. Therefore, it is reasonable to propose that 
HZ, depriving iNOS of l-Arg and thus lowering the pro-
duction of NO, may also be indirectly involved in the reg-
ulation of malaria transmission.
Conclusions
In conclusion, HZ, at doses higher than 25 µM, reduced 
l-Arg availability in  vitro and thus decreased NO pro-
duction by IFN-γ-primed BMDM (Fig.  6). These find-
ings could open new insights into the possible causes 
of hypoargininaemia, and the consequent low NO lev-
els, observed in  vivo. However, further investigations 
are needed to verify the possible implication in clinical 
severe malaria.
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Fig. 6 Diagram showing the hypothesis of interaction between HZ and l-Arg. Free or macrophage-phagocytosed HZ may interact with l-Arg 
(HZ-l-Arg). Depending on the concentration of HZ, different amounts of l-Arg may be trapped, affecting NO production. At 25 µM, HZ does not 
remove all the l-Arg (iNOS substrate) and NO is produced by macrophages; at 100 µM, HZ removes almost all l-Arg impairing NO production
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Abbreviations
HZ: natural haemozoin; βH: beta-hematin; BMDM: immortalized bone marrow 
macrophages; NO: nitric oxide; IFN-γ: interferon-gamma; L-Arg: l-arginine; 
MDP: muramyldipeptide; LPS: lipopolysaccharide; ROS: reactive oxygen spe-
cies; TBHP: tert-butyl hydroperoxide; iNOS: inducible nitric oxide synthase; 
CM: conditioned medium; U-CM: untreated conditioned medium; HZ-CM: 
haemozoin-treated conditioned medium; LC–MS/MS: liquid chromatography-
tandem mass spectrometry.
Authors’ contributions
YC, SD, SP, DS, PK, SZ, FG performed experiments; YC, SD, DC, IC, TE, NB ana-
lyzed results; YC and NB designed the research; YC and SD made the figures. 
YC wrote the paper. All the authors contributed equally in the revision of the 
final manuscript. All authors read and approved the final manuscript.
Author details
1 Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli 
Studi di Milano, 20133 Milan, MI, Italy. 2 Dipartimento di Bioscienze, Università 
degli Studi di Milano, 20133 Milan, MI, Italy. 3 Dipartimento di Scienze 
Biomediche, Chirurgiche e Odontoiatriche, Università degli Studi di Milano, 
20133 Milan, MI, Italy. 4 Department of Immunology, Tufts University School 
of Medicine, Boston, MA 02111, USA. 5 Department of Chemistry, University 
of Cape Town, Private Bag X3, Rondebosch 7701, South Africa. 
Acknowledgements
The authors thank Prof. Donatella Taramelli for helpful discussion and con-
tributions, and Dr. Paola Misiano (Università degli Studi di Milano, Italy) for 
review the manuscript; Drs. Douglas Golenbock and Kate Fitzgerald (University 
of Massachusetts, USA) for providing BMDM; Drs. Laura Galastri, Paola Verducci, 
and Tiziana Bianchi (AVIS Comunale Milano, Italy) for providing blood samples 
for parasite cultures.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Not applicable.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Funding
This work was supported by “Ministero dell’Istruzione, dell’Università e della 
Ricerca (PRIN)” (Grant Number 20154JRJPP_004); and Global Health Program of 
the Bill & Melinda Gates Foundation (Grant OPP1040394).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 16 March 2018   Accepted: 29 November 2018
References
 1. WHO. World malaria report 2017. Geneva: World Health Organization; 
2017.
 2. Dondorp AM, Pongponratn E, White NJ. Reduced microcirculatory flow 
in severe falciparum malaria: pathophysiology and electron-microscopic 
pathology. Acta Trop. 2004;89:309–17.
 3. Stevenson MM, Riley EM. Innate immunity to malaria. Nat Rev Immunol. 
2004;4:169–80.
 4. Sobolewski P, Gramaglia I, Frangos J, Intaglietta M, van der Heyde HC. 
Nitric oxide bioavailability in malaria. Trends Parasitol. 2005;21:415–22.
 5. Serirom S, Raharjo WH, Chotivanich K, Loareesuwan S, Kubes P, Ho M. 
Anti-adhesive effect of nitric oxide on Plasmodium falciparum cytoadher-
ence under flow. Am J Pathol. 2003;162:1651–60.
 6. Clark IA, Rockett KA, Burgner D. Genes, nitric oxide and malaria in African 
children. Trends Parasitol. 2003;19:335–7.
 7. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, McNeil YR, 
et al. Impaired nitric oxide bioavailability and l-arginine reversible 
endothelial dysfunction in adults with falciparum malaria. J Exp Med. 
2007;204:2693–704.
 8. Lopansri BK, Anstey NM, Weinberg JB, Stoddard GJ, Hobbs MR, Levesque 
MC, et al. Low plasma arginine concentrations in children with cerebral 
malaria and decreased nitric oxide production. Lancet. 2003;361:676–8.
 9. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, McNeil YR, 
et al. Recovery of endothelial function in severe falciparum malaria: 
relationship with improvement in plasma l-arginine and blood lactate 
concentrations. J Infect Dis. 2008;198:602–8.
 10. Rey J, Buffet PA, Ciceron L, Milon G, Mercereau-Puijalon O, Safeukui I. 
Reduced erythrocyte deformability associated with hypoargininemia 
during Plasmodium falciparum malaria. Sci Rep. 2014;4:3767.
 11. Weinberg JB, Lopansri BK, Mwaikambo E, Granger DL. Arginine, nitric 
oxide, carbon monoxide, and endothelial function in severe malaria. 
Curr Opin Infect Dis. 2008;21:468–75.
 12. Higgins SJ, Kain KC, Liles WC. Immunopathogenesis of falciparum 
malaria: implications for adjunctive therapy in the management of 
severe and cerebral malaria. Expert Rev Anti Infect Ther. 2011;9:803–19.
 13. Gramaglia I, Sobolewski P, Meays D, Contreras R, Nolan JP, Frangos 
JA, et al. Low nitric oxide bioavailability contributes to the genesis of 
experimental cerebral malaria. Nat Med. 2006;12:1417–22.
 14. Serghides L, Kim H, Lu Z, Kain DC, Miller C, Francis RC, et al. Inhaled 
nitric oxide reduces endothelial activation and parasite accumulation 
in the brain, and enhances survival in experimental cerebral malaria. 
PLoS ONE. 2011;6:e27714.
 15. Martins YC, Zanini GM, Frangos JA, Carvalho LJ. Efficacy of different 
nitric oxide-based strategies in preventing experimental cerebral 
malaria by Plasmodium berghei ANKA. PLoS ONE. 2012;7:e32048.
 16. Cabrales P, Zanini GM, Meays D, Frangos JA, Carvalho LJ. Nitric oxide 
protection against murine cerebral malaria is associated with improved 
cerebral microcirculatory physiology. J Infect Dis. 2011;203:1454–63.
 17. Yeo TW, Lampah DA, Rooslamiati I, Gitawati R, Tjitra E, Kenangalem E, 
et al. A randomized pilot study of l-arginine infusion in severe falcipa-
rum malaria: preliminary safety, efficacy and pharmacokinetics. PLoS 
ONE. 2013;8:e69587.
 18. Mwanga-Amumpaire J, Carroll RW, Baudin E, Kemigisha E, Nampijja 
D, Mworozi K, et al. Inhaled nitric oxide as an adjunctive treatment for 
cerebral malaria in children: a phase II randomized open-label clinical 
trial. Open Forum Infect Dis. 2015;2:ofv111.
 19. Perkins DJ, Were T, Davenport GC, Kempaiah P, Hittner JB, Ong’echa JM. 
Severe malarial anemia: innate immunity and pathogenesis. Int J Biol 
Sci. 2011;7:1427–42.
 20. Ihekwereme CP, Esimone CO, Nwanegbo EC. Hemozoin inhibition and 
control of clinical malaria. Adv Pharmacol Sci. 2014;2014:984150.
 21. Lyke KE, Diallo DA, Dicko A, Kone A, Coulibaly D, Guindo A, et al. 
Association of intraleukocytic Plasmodium falciparum malaria pigment 
with disease severity, clinical manifestations, and prognosis in severe 
malaria. Am J Trop Med Hyg. 2003;69:253–9.
 22. Nguyen PH, Day N, Pram TD, Ferguson DJ, White NJ. Intraleucocytic 
malaria pigment and prognosis in severe malaria. Trans R Soc Trop Med 
Hyg. 1995;89:200–4.
Page 12 of 13Corbett et al. Malar J          (2018) 17:456 
 23. Omodeo-Salè F, Cortelezzi L, Vommaro Z, Scaccabarozzi D, Dondorp 
AM. Dysregulation of l-arginine metabolism and bioavailability associ-
ated to free plasma heme. Am J Physiol Cell Physiol. 2010;299:C148–54.
 24. Uyen DT, Huy NT, Trang DT, Nhien NT, Oida T, Hirayama K, et al. Effects 
of amino acids on malarial heme crystallization. Biol Pharm Bull. 
2008;31:1483–8.
 25. Kalantari P, Deoliveira RB, Chan J, Corbett Y, Rathinam V, Stutz A, 
et al. Dual engagement of the NLRP3 and AIM2 inflammasomes by 
Plasmodium-derived hemozoin and DNA during malaria. Cell Rep. 
2014;6:196–210.
 26. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. 
Silica crystals and aluminum salts activate the NALP3 inflammasome 
through phagosomal destabilization. Nat Immunol. 2008;9:847–56.
 27. Trager W, Jensen JB. Human malaria parasites in continuous culture. 
Science. 1976;193:673–5.
 28. Corbett Y, Parapini S, D’Alessandro S, Scaccabarozzi D, Rocha BC, Egan 
TJ, et al. Involvement of Nod2 in the innate immune response elicited 
by malarial pigment hemozoin. Microbes Infect. 2015;17:184–94.
 29. Egan TJ. Physico-chemical aspects of hemozoin (malaria pigment) 
structure and formation. J Inorg Biochem. 2002;91:19–26.
 30. Prato M, D’Alessandro S, Van den Steen PE, Opdenakker G, Arese P, 
Taramelli D, et al. Natural haemozoin modulates matrix metallopro-
teinases and induces morphological changes in human microvascular 
endothelium. Cell Microbiol. 2011;13:1275–85.
 31. Griess J. Bemerkungen zu der Abhandlung der H.H. Weselsky und 
Benedikt “Ueber einige Azoverbindungen”. Chemische Berichte. 
1879;12:426–8.
 32. Skorokhod OA, Schwarzer E, Ceretto M, Arese P. Malarial pigment haemo-
zoin, IFN-gamma, TNF-alpha, IL-1beta and LPS do not stimulate expres-
sion of inducible nitric oxide synthase and production of nitric oxide in 
immuno-purified human monocytes. Malar J. 2007;6:73.
 33. Jung JY, Madan-Lala R, Georgieva M, Rengarajan J, Sohaskey CD, Bange 
FC, et al. The intracellular environment of human macrophages that 
produce nitric oxide promotes growth of mycobacteria. Infect Immun. 
2013;81:3198–209.
 34. Bradford MM. A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding. 
Anal Biochem. 1976;72:248–54.
 35. Vishwanathan K, Tackett RL, Stewart JT, Bartlett MG. Determination of 
arginine and methylated arginines in human plasma by liquid chroma-
tography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 
2000;748:157–66.
 36. Sun J, Druhan LJ, Zweier JL. Reactive oxygen and nitrogen species 
regulate inducible nitric oxide synthase function shifting the balance 
of nitric oxide and superoxide production. Arch Biochem Biophys. 
2010;494:130–7.
 37. Jaramillo M, Godbout M, Olivier M. Hemozoin induces macrophage 
chemokine expression through oxidative stress-dependent and -inde-
pendent mechanisms. J Immunol. 2005;174:475–84.
 38. Taramelli D, Recalcati S, Basilico N, Olliaro P, Cairo G. Macrophage precon-
ditioning with synthetic malaria pigment reduces cytokine production 
via heme iron-dependent oxidative stress. Lab Invest. 2000;80:1781–8.
 39. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. 
Nod2 is a general sensor of peptidoglycan through muramyl dipeptide 
(MDP) detection. J Biol Chem. 2003;278:8869–72.
 40. Rush GF, Gorski JR, Ripple MG, Sowinski J, Bugelski P, Hewitt WR. Organic 
hydroperoxide-induced lipid peroxidation and cell death in isolated 
hepatocytes. Toxicol Appl Pharmacol. 1985;78:473–83.
 41. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, 
et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by 
type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by 
the pattern of l-arginine metabolism. J Immunol. 2001;167:6533–44.
 42. Munder M, Eichmann K, Morán JM, Centeno F, Soler G, Modolell M. Th1/
Th2-regulated expression of arginase isoforms in murine macrophages 
and dendritic cells. J Immunol. 1999;163:3771–7.
 43. Rutschman R, Lang R, Hesse M, Ihle JN, Wynn TA, Murray PJ. Cutting edge: 
Stat6-dependent substrate depletion regulates nitric oxide production. J 
Immunol. 2001;166:2173–7.
 44. Parroche P, Lauw FN, Goutagny N, Latz E, Monks BG, Visintin A, et al. 
Malaria hemozoin is immunologically inert but radically enhances innate 
responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl 
Acad Sci USA. 2007;104:1919–24.
 45. Barrera V, Skorokhod OA, Baci D, Gremo G, Arese P, Schwarzer E. Host 
fibrinogen stably bound to hemozoin rapidly activates monocytes via 
TLR-4 and CD11b/CD18-integrin: a new paradigm of hemozoin action. 
Blood. 2011;117:5674–82.
 46. Ambele MA, Egan TJ. Neutral lipids associated with haemozoin mediate 
efficient and rapid β-haematin formation at physiological pH, tempera-
ture and ionic composition. Malar J. 2012;11:337.
 47. Olliaro P, Lombardi L, Frigerio S, Basilico N, Taramelli D, Monti D. Phagocy-
tosis of hemozoin (native and synthetic malaria pigment), and Plasmo-
dium falciparum intraerythrocyte-stage parasites by human and mouse 
phagocytes. Ultrastruct Pathol. 2000;24:9–13.
 48. Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, et al. Toll-like 
receptor 9 mediates innate immune activation by the malaria pigment 
hemozoin. J Exp Med. 2005;201:19–25.
 49. Shio MT, Tiemi Shio M, Eisenbarth SC, Savaria M, Vinet AF, Bellemare MJ, 
et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn 
and Syk kinases. PLoS Pathog. 2009;5:e1000559.
 50. Jaramillo M, Gowda DC, Radzioch D, Olivier M. Hemozoin increases IFN-
gamma-inducible macrophage nitric oxide generation through extracel-
lular signal-regulated kinase- and NF-kappa B-dependent pathways. J 
Immunol. 2003;171:4243–53.
 51. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. 
Annu Rev Immunol. 1997;15:323–50.
 52. Mattila JT, Thomas AC. Nitric oxide synthase: non-canonical expression 
patterns. Front Immunol. 2014;5:478.
 53. Boutlis CS, Tjitra E, Maniboey H, Misukonis MA, Saunders JR, Suprianto S, 
et al. Nitric oxide production and mononuclear cell nitric oxide synthase 
activity in malaria-tolerant Papuan adults. Infect Immun. 2003;71:3682–9.
 54. Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga 
D, Misukonis MA, et al. Nitric oxide in Tanzanian children with malaria: 
inverse relationship between malaria severity and nitric oxide produc-
tion/nitric oxide synthase type 2 expression. J Exp Med. 1996;184:557–67.
 55. Miller LH, Ackerman HC, Su XZ, Wellems TE. Malaria biology and disease 
pathogenesis: insights for new treatments. Nat Med. 2013;19:156–67.
 56. Keller CC, Kremsner PG, Hittner JB, Misukonis MA, Weinberg JB, Perkins 
DJ. Elevated nitric oxide production in children with malarial anemia: 
hemozoin-induced nitric oxide synthase type 2 transcripts and nitric 
oxide in blood mononuclear cells. Infect Immun. 2004;72:4868–73.
 57. Yeo TW, Lampah DA, Tjitra E, Gitawati R, Kenangalem E, Piera K, et al. 
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide 
bioavailability and perfusion in severe falciparum malaria. J Infect Dis. 
2009;200:1522–9.
 58. Olszewski KL, Morrisey JM, Wilinski D, Burns JM, Vaidya AB, Rabinowitz 
JD, et al. Host-parasite interactions revealed by Plasmodium falciparum 
metabolomics. Cell Host Microbe. 2009;5:191–9.
 59. Yeo TW, Lampah DA, Tjitra E, Gitawati R, Darcy CJ, Jones C, et al. Increased 
asymmetric dimethylarginine in severe falciparum malaria: association 
with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog. 
2010;6:e1000868.
 60. Yeo TW, Lampah DA, Kenangalem E, Tjitra E, Price RN, Weinberg JB, et al. 
Impaired systemic tetrahydrobiopterin bioavailability and increased 
dihydrobiopterin in adult falciparum malaria: association with disease 
severity, impaired microvascular function and increased endothelial 
activation. PLoS Pathog. 2015;11:e1004667.
 61. Weinberg JB, Yeo TW, Mukemba JP, Florence SM, Volkheimer AD, Wang H, 
et al. Dimethylarginines: endogenous inhibitors of nitric oxide synthesis 
in children with falciparum malaria. J Infect Dis. 2014;210:913–22.
 62. Dowling DP, Ilies M, Olszewski KL, Portugal S, Mota MM, Llinás M, et al. 
Crystal structure of arginase from Plasmodium falciparum and impli-
cations for l-arginine depletion in malarial infection. Biochemistry. 
2010;49:5600–8.
 63. Alkaitis MS, Wang H, Ikeda AK, Rowley CA, MacCormick IJ, Chertow JH, 
et al. Decreased rate of plasma arginine appearance in murine malaria 
may explain hypoargininemia in children with cerebral malaria. J Infect 
Dis. 2016;214:1840–9.
 64. Aguilar R, Moraleda C, Achtman AH, Mayor A, Quintó L, Cisteró P, et al. 
Severity of anaemia is associated with bone marrow haemozoin in chil-
dren exposed to Plasmodium falciparum. Br J Haematol. 2014;164:877–87.
Page 13 of 13Corbett et al. Malar J          (2018) 17:456 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 65. Choi BS, Martinez-Falero IC, Corset C, Munder M, Modolell M, Müller 
I, et al. Differential impact of l-arginine deprivation on the activa-
tion and effector functions of T cells and macrophages. J Leukoc Biol. 
2009;85:268–77.
 66. Aguilar R, Magallon-Tejada A, Achtman AH, Moraleda C, Joice R, Cisteró 
P, et al. Molecular evidence for the localization of Plasmodium falciparum 
immature gametocytes in bone marrow. Blood. 2014;123:959–66.
 67. Farfour E, Charlotte F, Settegrana C, Miyara M, Buffet P. The extravascular 
compartment of the bone marrow: a niche for Plasmodium falciparum 
gametocyte maturation? Malar J. 2012;11:285.
 68. Tibúrcio M, Niang M, Deplaine G, Perrot S, Bischoff E, Ndour PA, et al. 
A switch in infected erythrocyte deformability at the maturation and 
blood circulation of Plasmodium falciparum transmission stages. Blood. 
2012;119:e172–80.
 69. Ramdani G, Naissant B, Thompson E, Breil F, Lorthiois A, Dupuy F, 
et al. cAMP-signalling regulates gametocyte-infected erythrocyte 
deformability required for malaria parasite transmission. PLoS Pathog. 
2015;11:e1004815.
 70. Casals-Pascual C, Kai O, Cheung JO, Williams S, Lowe B, Nyanoti M, et al. 
Suppression of erythropoiesis in malarial anemia is associated with 
hemozoin in vitro and in vivo. Blood. 2006;108:2569–77.
